Contribute Try STAT+ Today

Just hours before one of its executives is set to testify at a Congressional hearing to review insulin pricing, Sanofi (SNY) on Wednesday offered a program that will lower the cost of the diabetes treatment to $99 a month for uninsured patients and others who pay cash in the U.S.

Under the plan, the drug maker maintained patients can buy up to 10 boxes of insulin pens or vials with a valid prescription, beginning in June, and expands a program that began a year ago in which patients were paying $99 for each vial of insulin and $149 for each pack of insulin pens.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Any individual can purchase a generic brand of insulin at Walmart pharmacy for less than $25.00 per vial. A prescription is not even required. I discovered this when my mother had no Rx coverage. It seems few people are aware of this.

Comments are closed.